Bill Rastetter
Partner, Venrock
Former Executive Chairman, Idec

Bill Rastetter joined Venrock in 2006, formerly executive chairman of Biogen Idec. Bill joined Idec Pharmaceuticals at its founding and grew it to a multi-billion-dollar market valuation company, while serving as president and CEO. Prior to Idec, he was Director of Corporate Ventures at Genentech, Inc. and served in a scientific capacity at Genentech. Adding to his corporate background, Bill held various faculty positions at MIT, won the award for "Excellence in the Teaching of Chemistry" at Harvard and is an Alfred P. Sloan Fellow. Bill is the author of numerous scientific papers and patent applications in the fields of organic and bio-organic chemistry, protein and enzyme engineering, and biotechnology. Bill currently serves on the board of Illumina, a Venrock alumni investment.

Paul J. Hastings
President and CEO
OncoMed Pharmaceuticals, Inc.

Mr. Hastings brings more than 20 years of experience as a biotechnology and pharmaceutical industry executive. He has served as President and CEO of OncoMed Pharmaceuticals since January 2006. Prior to joining OncoMed, Mr. Hastings was President and Chief Executive Officer of QLT, Inc. Previous to that, Mr. Hastings served as President and Chief Executive Officer of Axys Pharmaceuticals, which was acquired by Celera Corporation in 2001. From 1999 to 2001, Mr. Hastings served as the President of Chiron BioPharmaceuticals, a division of Chiron Corporation. Prior to that, he was President and Chief Executive Officer of LXR Biotechnology. Mr. Hastings also held a series of management positions of increasing responsibility at Genzyme Corporation, including serving as President of Genzyme Therapeutics Europe as well as President of Worldwide Therapeutics. Mr. Hastings also served as Vice President, Marketing and Sales and General Manager, Europe for Synergen, Inc., and previously held a series of marketing and sales management positions with Hoffmann-La Roche. Mr Hastings was recently Chairman of the Board of Proteolix (sold to Onyx Pharmaceuticals in 2009), and served on the boards of ViaCell (sold to Perkin-Elmer in 2008), and Cerimon Pharmaceuticals. He is currently Chairman of the Board of the Bay Area Biosciences Association (Bay Bio) and serves on the executive committee of the board of directors of the Biotechnology Industry Association. He received a Bachelor of Science degree in pharmacy from the University of Rhode Island.

Anthony (Tony) Coles, MD, MPH
President and CEO
Onyx Pharmaceuticals, Inc.

Dr. Coles joined Onyx in March 2008 as President, Chief Executive Officer, and a member of its Board of Directors. Prior to joining Onyx, he was President, Chief Executive Officer, and a member of the Board of Directors of NPS Pharmaceuticals, Inc. Before joining NPS Pharmaceuticals in 2005, Dr. Coles was Senior Vice President of Commercial Operations at Vertex Pharmaceuticals Incorporated, which he joined in 2002. Beginning in 1996, he held a number of executive positions while at Bristol-Myers Squibb Company, including Senior Vice President of Strategy and Policy; Senior Vice President of Marketing and Medical Affairs, Neuroscience/Infectious Diseases/Dermatology; Vice President, Western Area Sales Cardiovascular and Metabolic Business Unit for U.S. Primary Care; and Vice President, Cardiovascular Global Marketing. From 1992 until 1996, Dr. Coles also held a number of positions of increasing responsibility at Merck & Co., Inc, including Vice President of the Hypertension and Heart Failure Business Group. Dr. Coles completed his cardiology and internal medicine training at Massachusetts General Hospital and was a research fellow at Harvard Medical School. He earned an M.D. degree from Duke University, a master's degree in public health from Harvard University, and an undergraduate degree from Johns Hopkins University. Dr. Coles currently serves as a trustee and member of the Executive Committee for the Johns Hopkins University Board of Trustees, as well as a member of the board of trustees for Johns Hopkins Medicine. He is also a member of the board of the Biotechnology Industry Organization (BIO).

Kim Popovits
CEO
Genomic Health, Inc.

Kim Popovits has served as President and Chief Executive Officer since January 2009 and as President and Chief Operating Officer since January 2002. From November 1987 to February 2002, Kim served in various roles at Genentech, Inc., a biotechnology company, most recently as Senior Vice President, Marketing and Sales from February 2001 to February 2002, and as Vice President, Sales from October 1994 to February 2001. Prior to joining Genentech in November 1987, she served as Division Manager for American Critical Care, a Division of American Hospital Supply. Kim holds a Bachelor of Arts degree in Business from Michigan State University.

Steven B. Engle
Chairman and CEO
XOMA (US) LLC

Mr. Engle was appointed chairman and chief executive officer of XOMA (US) LLC in 2007. With more than 25 years of executive leadership and biotechnology and pharmaceutical industry experience, his expertise spans the areas of therapeutic products, operations and corporate development. He previously served as chairman of the board and chief executive officer of La Jolla Pharmaceutical Company, a publicly-held biopharmaceutical company focused on the research and development of therapeutic products for autoimmune and antibody-mediated diseases. He joined La Jolla Pharmaceutical Company in 1993, became president and a director in 1994, CEO in 1995, and chairman of the board in 1997. Prior to joining La Jolla, he held executive-level positions at Cygnus Therapeutic Systems, a developer of drug delivery systems, and Micro Power Systems, Inc., a manufacturer of high technology products, including medical devices. He began his professional career with the Strategic Decisions Group and the Stanford Research Institute. Mr. Engle is a member of the Emerging Companies Section Governing Board Executive Committee for BIO, the biotechnology industry's trade association, and a member of the Board of Directors of BayBio, the non-profit association serving the Northern California life sciences industry. Mr. Engle is a graduate of the University of Texas with B.S. and M.S. degrees in biomedical engineering.

John Mendlein
Executive Chairman
Fate Therapeutics
aTyr Pharm
Chimeros
Alevium

Dr. John Mendlein is Executive Chairman of four privately held biotech companies in San Diego: Fate Therapeutics (drugs for stem cells), aTyr Pharm (novel protein therapeutics), Chimeros (novel polynucleotide therapeutics) and Alevium (novel drugs for GI discomfort). Prior to his involvement in these enterprises, he served as CEO of Adnexus Therapeutics (a pioneer of a new class of protein therapeutics) from June 2005 until October 2007, at which time the privately-held, Boston based biotechnology company was purchased by Bristol-Myers Squibb Company (BMY). Previously, Mendlein served as Chairman and CEO at Affinium Pharmaceuticals, Inc.; and served in a variety of roles, including board member, general counsel and chief knowledge officer, at Aurora Biosciences (acquired by Vertex Pharmaceuticals, VRTX) a biotechnology company focused on discovering drugs for kinases, g-protein coupled receptors and ion channels. He has worked as an attorney at Cooley LLP, a law firm, in its life sciences and technology litigation practice groups; at Smith Kline & French, now GlaxoSmithKline (GSK), a scientist in the Department of Molecular Biology and Protein Expression; and served as a board member of Monogram Biosciences (MGRM, acquired by Lab Corp, LH). He is currently an advisory board member of Genesys Capital a venture capital firm in Canada, a founder and board member of Homes for Sudan a not for profit in Boston, and a scientific advisory board member for Ocean Discovery Institute a not for profit in San Diego. He is the author or inventor of over 40 publications and patents. He has won various awards for his work in biotechnology and science, as well as write-ups of various business endeavors in the Wall Street Journal, Financial Times and Newsweek. Mendlein earned his Ph.D. in physiology and biophysics from the University of California, Los Angeles, a J.D. from the University of California Hastings School of Law and a B.S. in biology from the University of Miami.

Julia P. Gregory
President and CEO
Five Prime Therapeutics, Inc.

Ms. Gregory has been our President and CEO since June 2009. She brings extensive biotechnology experience in financing, strategic alliances and transactions, operations and executive management. She was formerly Executive Vice President and Chief Financial Officer of Lexicon Pharmaceuticals, Inc. where she was responsible for the company's financing strategies, mergers and acquisitions, business operations and all financial management and accounting functions. She raised approximately $1 billion in public and private equity transactions, product development financing and strategic business development transactions, including Lexicon's $220 million initial public offering, a private equity agreement for $550 million in financing and a $60 million product financing collaboration. Prior to joining Lexicon, Ms. Gregory served as the head of investment banking for Punk, Ziegel & Company, a specialty investment banking firm focusing on technology and healthcare and served as the head of the firm's life sciences practice. Prior to Punk, Ziegel & Company, she was an investment banker with Dillon, Read & Co., Inc., where she represented life sciences companies beginning in 1986. Ms. Gregory is a member of the board of directors of The Global TB Alliance for Drug Development and the Lauder Foundation's Institute for the Study of Aging, Inc. She received her B.A. in international affairs from George Washington University and her M.B.A. from the Wharton School of the University of Pennsylvania.

John "Chip" Scarlett
Executive Chairman
Vega Therapeutics, Inc.

Kleanthis G. Xanthopoulos, PhD
President and Chief Executive Officer
Regulus Therapeutics, Inc.

Kleanthis G. Xanthopoulos, PhD has been the President & Chief Executive Officer of Regulus Therapeutics, Inc. since December 2007. Before joining Regulus, shortly after its formation, Dr. Xanthopoulos was a managing director of Enterprise Partners Venture Capital. Prior to that, he was a co-founder and served as President and Chief Executive Officer and Director of Anadys Pharmaceuticals (NASDAQ:ANDS) from its inception in May 2000 to November 2006. From 1997 to 2000 he was at Aurora Biosciences (acquired by Vertex Pharmaceuticals) serving as Vice President. Dr. Xanthopoulos participated in The National Institutes of Health Human Genome Project and was a Section Head of the National Human Genome Research Institute from 1995 to 1997. He was an Associate Professor of Molecular Biology at the Karolinska Nobel Medical Institute, Stockholm, Sweden from 1991 to 1995, and a Postdoctoral Research Fellow at The Rockefeller University from 1987 to 1990. An Onassis scholar, Dr. Xanthopoulos received his B.Sc. in Biology with honors from Aristotle University of Thessaloniki, Greece, and received both his M.Sc. in Microbiology and PhD in Molecular Biology from the University of Stockholm, Sweden. Dr. Xanthopoulos is a member of the board of directors of Anadys Pharmaceuticals Inc., Sente Inc., and an executive board member of BIOCOM, Southern California's life science industry association, where he chairs the Capital Formation Committee.

Hollings C. Renton

Hollings C. Renton retired from Onyx Pharmaceuticals, Inc. on March 31, 2008. Since June 2003, Mr. Renton served as Chairman of the Board of Onyx, a biopharmaceutical company, where he also served as President and Chief Executive Officer since March 1993 and a director since April 1992. Hollings led Onyx in its collaboration with Bayer Healthcare Pharmaceuticals in developing and commercializing Nexavar® (sorafenib) tablets, a novel, oral multiple kinase inhibitor that targets proteins involved in both tumor cell proliferation and angiogenesis. Nexavar is approved in more than 90 countries for the treatment of patients with unresectable liver cancer and in more than 95 countries for the treatment of patients with advanced kidney cancer. As part of a broad clinical development program, Nexavar is also being evaluated in multiple Phase 3 and Phase 2 trials as a single agent or combination treatment in a wide range of cancers, including lung cancer, thyroid cancer, breast cancer, colorectal cancer, ovarian cancer, and as an adjuvant therapy for liver cancer and kidney cancer.

From 1991 to 1993, he served as President and Chief Operating Officer of Chiron Corporation, a pharmaceutical company, following its acquisition of Cetus Corporation. Prior to the acquisition, he served as President of Cetus Corporation from 1990 to 1991, as Chief Operating Officer from 1987 to 1990 and Chief Financial Officer from 1983 to 1987. Scientists at Cetus Corporation were responsible for the discovery and development of Polymerase Chain Reaction (PCR), Betaseron and Proleukin. PCR is one of the most important discoveries in biotechnology allowing replication of millions of copies of DNA. Carey Mullis discovered PCR and received the Nobel Prize for his work. Betaseron, a form of beta interferon is a mainstay in the treatment of multiple sclerosis. Proleukin interleukin-2 is approved for the treatment of kidney cancer.

Mr. Renton is Chairman of Affymax Inc. and Co-chairman and lead director of Portola Pharmaceuticals. He also serves as a member of the Boards of Directors of Cepheid Corporation, Rigel Pharmaceuticals and Special Olympics of Northern California. Mr. Renton has a Masters of Business Administration from the University of Michigan and a Bachelors of Science from Colorado State University.

Brook Byers
Partner
Kleiner, Perkins, Caufield & Byers

Brook Byers has been a venture capital investor since 1972. He has been closely involved with more than fifty new technology-based ventures, over half of which have already become public companies. He formed the first life sciences practice group in the venture capital profession in 1984 and led Kleiner Perkins Caufield & Byers (KPCB) to become a premier venture capital firm in the medical, health care, and biotechnology sectors. KPCB has invested in and helped build over 110 life sciences companies which have already developed hundreds of products to treat major underserved medical needs for millions of patients. Brook's leadership and direction have propelled pioneering companies in the fields of molecular biology, monoclonal antibodies, personalized medicine, molecular diagnostsics and genomics. His sense of community and commitment to civic responsibility have helped several community-based organizations, including the BayBio Institute, University of California San Francisco, Stanford University, American Academy of Arts and Sciences, National Venture Capital Association and many more.

Samuel D. Colella
Managing Director
Versant Ventures

Samuel Colella has been a venture capital investor since 1984. Recognized for his leadership in life science investing, Mr. Colella co-founded Versant Ventures with six partners in 1999. Prior to founding Versant, he launched one of the first life science investing groups in the industry as a General Partner at Institutional Venture Partners.

Over the course of his venture career, in addition to building two major venture capital firms, Mr. Colella has served as a Director on over 30 health care companies. He is credited with an extensive list of successful public life science companies, including Alexza Pharmaceuticals, Argonaut Technologies, Arthrocare, Athena Neurosciences, Aviron, CV Therapeutics, Endosonics, Genomic Health Inc., IVAC Holdings, Onyx Pharmaceuticals, Pharmacopeia, Symyx Technologies, Thermage, Tularik and Vivus. He is currently a director of Alexza Pharmaceuticals, EuroVentures, Flexion, Genomic Health Inc., Jazz Pharmaceuticals, Rennovia, Veracyte, and he is Chairman of Fluidigm.

Mr. Colella was President of a New York Stock Exchange company and held a variety of functional positions in a broad array of diverse businesses, including president of Spectra-Physics, the world's leading laser supplier, and senior manager of the Technical Products Division of Corning Glass.

Mr. Colella's professional affiliations include terms of service as an officer in the National Venture Capital Association, the Western Association of Venture Capitalists, and American Entrepreneurs for Economic Growth and he is currently Chairman of the Stanford Council on Interdisciplinary Biosciences. In 2001, Mr. Colella was awarded with the Distinguished Athletic Letterman from the University of Pittsburgh. In 2002, he was inducted into the University of Pittsburgh's Legacy Laureate Society. In 2005, he received the American Liver Foundation's Salute to Excellence Award. In 2010, he received the Lifetime Achievement Award from the National Venture Capital Association. Mr. Colella has a B.S. degree in Business and Engineering from the University of Pittsburgh and an M.B.A. degree from Stanford University.

Bryan Roberts, PhD
Partner
Venrock

Bryan Roberts joined Venrock as a Kauffman Fellow in 1997. Previously, he earned his PhD in Chemistry & Chemical Biology at Harvard University and, prior to his doctoral program, held corporate finance positions at Kidder, Peabody and Co. Bryan was named a Henry Crown Fellow by the Aspen Institute in 2006, he was named to healthspottr's 2009 Future Health 100 list and was the highest-ranking healthcare investor on Forbes' Midas List in 2008 and 2009.

Vaughn M. Kailian
Managing Director
MPM Capital

Vaughn Kailian joined MPM's Boston office in 2005 and brought to MPM unparalleled success in the stewardship of commercial biotech and pharmaceutical companies. From 2002 - 2004, he served as vice chair of the Board of Directors of Millennium Pharmaceuticals, Inc.; and was head of the Millennium commercial organization. From 1990 - 2002, Mr. Kailian served as CEO, president and director of COR Therapeutics, Inc. He became the CEO of COR shortly after the company was founded, took the company public in 1991, raised almost $1 billion in public market capital, and led the $2 billion merger with Millennium in 2002. Earlier in his career, Mr. Kailian held various international and U.S. general management, marketing and sales positions at Marion Merrell Dow, Inc. and its predecessor companies including president and general manager, Merrell Dow USA; and corporate vice president of Global Commercial Development, Marion Merrell Dow, Inc. He earned his B.A. degree at Tufts University. Mr. Kailian is also a member of the board of BIO Ventures for Global Health and the New England Healthcare Institute.

David L. Gollaher, PhD
President and CEO
California Healthcare Institute, Inc.

David L. Gollaher, PhD, co-founded CHI in 1993. Previously he was a senior executive at Scripps Clinic and Research Foundation. Earlier in his career, he served on the faculties of Harvard University, University of California, San Diego, the Graduate School of Public Health at SDSU, and the Overseas School of Rome. He is an award-winning historian of science and medicine, and has written three books and numerous articles in the fields of health policy, the economics of biomedical research and development, bioethics and the history of medicine. Gollaher completed his undergraduate studies at the University of California and earned his master's and doctorate degrees from Harvard University. Subsequently he was a Fellow of Harvard's Houghton Library, the National Endowment for the Humanities, and the Massachusetts Historical Society. Presently he serves on the boards of CHI, the J. David Gladstone Institutes and sits on the California Council on Science and Technology (CCST) and the Biotechnology Advisory Committee of the California Commission for Economic Development (CED). Gollaher is also a co-founder and board member of Vision Robotics Corporation, and holds five patents for vision-based autonomous robotic navigation software.

Gail Maderis
President and CEO
BayBio

Gail Maderis is President & CEO of BayBio, the industry organization representing and supporting Northern California's life science community. As a former biotech CEO, Ms. Maderis brings deep experience and commitment to supporting the industry through enterprise development, peer-to-peer experience sharing, advocacy and support of education and workforce development. From 2003 to 2009, Ms. Maderis served as President and CEO of Five Prime Therapeutics, Inc., a privately held protein discovery and development company. At FivePrime, she successfully funded the company's rapid growth through substantial private equity financings and corporate partnerships and took the company's first novel cancer therapeutic from discovery into clinical trials. Prior to FivePrime, Ms. Maderis held senior executive positions at Genzyme Corporation, including founder and president of Genzyme Molecular Oncology (GZMO). Ms. Maderis practiced management and strategy consulting with Bain & Co. She serves on the boards of BayBio, the Mayor's Biotech Advisory Council of San Francisco and the HBS Healthcare Initiative. She received a BS in business from the UC Berkeley and an MBA from Harvard Business School.

Joseph D. Panetta
President and CEO
BIOCOM

Joseph Panetta is president and CEO and a member of the board of directors of BIOCOM since 1999. Panetta has been actively involved in the health sciences and government arenas for more than 25 years, having begun his professional career in 1979 with the U.S. Environmental Protection Agency in Washington D.C. where he became the youngest senior policy analyst within the Reagan Administration. In 1984 Panetta joined Pennwalt Corporation, a Fortune 500 pharmaceutical and chemical company, where he led the global regulatory affairs program within the agrichemicals division, and was actively involved in new business acquisition. In 1988 he came to San Diego to join Mycogen Corporation where, as vice president of government and public affairs, he played a principal role in obtaining U.S. and worldwide regulatory approvals of the first genetically engineered microbes and crops. His global responsibilities included serving as chairman of Mycogen Mexico and as a board member of Mycogen France. After participating in the divestiture of Mycogen to The Dow Chemical Company in 1998, he served briefly as global leader of government and regulatory affairs for the Plant Sciences Division of Dow AgroSciences before taking the helm at BIOCOM. He has advised the National Academy of the Sciences on biotechnology safety issues, has been a delegate to the Global Consultation on Safety in Biotechnology under the auspices of the United Nations Environmental Program, and he is a member of the U.S. Council on Competitiveness' Mexico-U.S. Biotechnology advisory board. He has testified before committees of the U.S. Congress and the California legislature on issues regarding biotechnology policy, regulatory affairs and international trade. In addition to his work as president and CEO of BIOCOM, Panetta's association involvement has included chairing the CropLife America Biotechnology Committee and serving as founding member of the International Biotechnology Forum under the auspices of the Biotechnology Industry Organization (BIO). He has served as chairman of the BIO Council of State Bioscience Associations. Panetta has been recognized for his advocacy work by the American Academy of Pharmaceutical Physicians and the Sidney Kimmel Cancer Center. Panetta holds a Bachelor of Science degree in biology from LeMoyne College in Syracuse, NY and a Master of Public Health degree in Industrial and Environmental Health from the University of Pittsburgh.